Welcome to our dedicated page for INSPIRE VETERINARY PARTNER SEC filings (Ticker: IVP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Wondering what drives profitability at a veterinary roll-up? Investors exploring Inspire Veterinary Partners SEC filings usually start with questions like, “Where can I see Inspire Veterinary Partners quarterly earnings report 10-Q filing?” or “How do I track Inspire Veterinary Partners insider trading Form 4 transactions in real time?” This page answers those needs by collecting every IVP disclosure the moment it hits EDGAR and layering Stock Titan’s AI summaries on top, so locating same-clinic revenue trends or new-hospital purchase prices no longer requires hours of scrolling.
Use the annual report—listed here as the Inspire Veterinary Partners annual report 10-K simplified—to dig into clinic-level margins, debt used to finance acquisitions, and veterinarian staffing costs. Drill further with each Inspire Veterinary Partners 8-K material events explained entry for rapid insight into freshly announced hospital buys or leadership changes. Need executive pay details? The Inspire Veterinary Partners proxy statement executive compensation section highlights them clearly, while AI notes potential alignment risks. And if you monitor ownership shifts, our feed of Inspire Veterinary Partners Form 4 insider transactions real-time flags each purchase or sale, helping you spot buying patterns before earnings season.
Every filing—10-K, 10-Q, 8-K, S-1, or Inspire Veterinary Partners earnings report filing analysis—comes with concise, plain-English explanations that transform legal prose into actionable points. Toggle AI-powered summaries to translate dense accounting language, set alerts for Inspire Veterinary Partners executive stock transactions Form 4, and compare quarter-over-quarter trends without leaving the page. It’s understanding Inspire Veterinary Partners SEC documents with AI—made straightforward, comprehensive, and always up to date.
Inspire Veterinary Partners, Inc. (IVP) is filing an S-1 that describes a roll-up veterinary business model driven by acquisitions of individual hospitals and related real estate. For the six months ended June 30, 2025, the company reported $16.59M of revenue (flat year-over-year) and a net loss of $5.45M, and it sustained a net loss of $3.03M for the three months ended June 30, 2025. Management discloses substantial acquisitions completed since 2021 (multiple clinics with transaction values reported) and ongoing financing from notes, convertible instruments, a common stock purchase agreement and other debt.
The filing discloses notes payable of approximately $11.98M, elevated interest expense and non-cash charges that contributed to a going-concern statement: management says additional financing is required to continue operations for the next 12 months. The prospectus also notes a Nasdaq listing deficiency and potential dilution from a range of outstanding warrants, options and preferred conversions totaling material share counts.
Erinn Thomas-Mackey, a director of Inspire Veterinary Partners, Inc. (IVP), reported acquiring 1,447 shares of Class A common stock through the exercise of a stock option on 09/26/2024. The option had a listed exercise price of $17 and the transaction leaves Ms. Thomas-Mackey with 1,447 shares held directly. The Form 4 notes the reported share amounts were adjusted for a 25-for-1 reverse stock split effected by the issuer on 01/27/2025.
The filing also discloses that this Form 4 was submitted late due to an inadvertent administrative error and bears a signature date of 09/22/2025.
Inspire Veterinary Partners, Inc. (IVP) filed an S-1 registration statement describing an offering of Class A common stock and related resale registration rights with investor Seven Knots, LLC. The company discloses it has a limited operating history, is not profitable, and has generated U.S. net operating loss carryforwards that may be unusable if future taxable income does not materialize. IVP lists numerous operational and regulatory risks including challenges integrating acquisitions, recruiting and retaining veterinarians, cybersecurity and data risks, compliance with state and federal veterinary and controlled-substance laws, and Nasdaq listing deficiency notices. The prospectus summarizes outstanding and potentially issuable equity: 3,609,285 Class A shares outstanding as of September 16, 2025; multiple tranches of warrants, options and convertible preferred stock that together could materially increase diluted shares (examples include 7,593,000 shares from conversion of Series B preferred, 1,092,896+1,092,896 warrants at $1.83, and 9,450,000 shares reserved under the 2022 Equity Incentive Plan). The offering contemplates up to 35,000,000 Class A shares in this offering on a pro forma as-adjusted basis and describes conditions required for purchase agreement effectiveness.
Inspire Veterinary Partners, Inc. (IVP) director Phillip Balatsos submitted an initial Form 3 stating he does not beneficially own any securities of the issuer. The filing notes the Form 3 was submitted late due to an inadvertent administrative error. The disclosure lists the relevant event date as 10/09/2024 and indicates the form was filed by a single reporting person.
Alexandra Quarti, identified as Vice President of Medical Operations, filed an initial Form 3 reporting her relationship to Inspire Veterinary Partners, Inc. (IVP) and the event date of 08/20/2025. The form states she does not beneficially own any securities of the issuer. The filing lists her business address in Virginia Beach, VA, and confirms this is an individual filing by one reporting person.
Laura Elizabeth Johnson, Vice President of Operations and a director-level reporting person for Inspire Veterinary Partners, Inc. (IVP), filed an initial Form 3 reporting the event dated 08/20/2025. The filing lists the reporting persons name and business address and explicitly states no securities are beneficially owned. The form is signed and dated 08/22/2025.
Armistice Capital, LLC and Steven Boyd report a 9.99% beneficial stake in Inspire Veterinary Partners, Inc. The Schedule 13G/A shows Armistice Capital (Delaware) and Steven Boyd (U.S.) collectively beneficially own 228,584 shares of Class A common stock (CUSIP G0360L134). The filing attributes shared voting and dispositive power over all 228,584 shares and reports no sole voting or dispositive power. The reporting parties say the shares are held in the ordinary course of business and not to influence control. The statement notes the Master Fund is the direct holder and Armistice Capital acts as investment manager.
Anne Murphy, identified as a director of Inspire Veterinary Partners, Inc. (ticker: IVP), reported a derivative security transaction on Form 4. The filing discloses an acquisition dated 09/26/2024 of a stock option (right to buy) covering 1,447 shares of Class A common stock with an exercise price of $17 per share. The options are shown as exercisable on 09/26/2024 and expiring on 09/26/2034, and the reported post-transaction beneficial ownership is 1,447 shares held directly.
The form notes that reported share counts have been adjusted for a 25-for-1 reverse stock split effected on 01/27/2025. The filing states it was submitted late due to an "inadvertent administrative error" and is signed by Anne Murphy with a signature date of 08/08/2025.
FAQ
What is the current stock price of INSPIRE VETERINARY PARTNER (IVP)?
What is the market cap of INSPIRE VETERINARY PARTNER (IVP)?
